TherapeuticsMD Inc (OQ:TXMD)

Business Focus: Specialty & Advanced Pharmaceuticals

Nov 14, 2023 04:05 pm ET
TherapeuticsMD Announces Third Quarter 2023 Financial Results
TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the third quarter ended September 30, 2023.
Aug 14, 2023 06:50 am ET
TherapeuticsMD Announces Second Quarter 2023 Financial Results
TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the second quarter ended June 30, 2023.
May 15, 2023 04:05 pm ET
TherapeuticsMD Announces First Quarter 2023 Financial Results
TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the first quarter ended March 31, 2023.
Apr 07, 2023 04:01 pm ET
TherapeuticsMD Announces Full Year 2022 Financial Results and Provides Update on Business Model Transition
TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the full year ended December 31, 2022.
Jan 03, 2023 06:50 am ET
TherapeuticsMD Completes Transaction to License Its Products to Mayne Pharma
TherapeuticsMD, Inc. (NASDAQ: TXMD) (“TherapeuticsMD,” “TXMD” or the “Company”), an innovative, leading women’s healthcare company, today announced that it has completed its previously announced transaction with Mayne Pharma Group Limited (“Mayne Pharma”), an ASX-listed specialty pharmaceutical company focused on commercializing novel and generic pharmaceuticals, pursuant to which TXMD granted Mayne Pharma an exclusive license to commercialize TXMD’s products in the United States. In addition, TXMD sold certain assets to Mayne Pharma to enable it to commercialize the products.
Dec 04, 2022 06:00 pm ET
TherapeuticsMD Announces Definitive Agreements to License its Products to Mayne Pharma
TherapeuticsMD, Inc. (NASDAQ: TXMD) (“TherapeuticsMD,” “TXMD” or the “Company”), an innovative, leading women’s healthcare company, today announced that it has entered into definitive agreements to license its products to an affiliate of Mayne Pharma Group Limited (“Mayne Pharma”), an ASX-listed specialty pharmaceutical company focused on commercializing novel and generic pharmaceuticals, for commercialization in the United States. In addition, TXMD has agreed to sell certain assets to Mayne Pharma to allow Mayne Pharma to commercialize the products.
Nov 14, 2022 04:05 pm ET
TherapeuticsMD Announces Third Quarter 2022 Financial Results
TherapeuticsMD, Inc. (“TXMD” or the “Company”) (NASDAQ: TXMD), an innovative, leading women’s healthcare company, today reported financial results for the third quarter ended September 30, 2022.
Oct 31, 2022 06:50 am ET
TherapeuticsMD Announces Additional $7 Million Private Placement
TherapeuticsMD, Inc. (NASDAQ: TXMD), (“TherapeuticsMD” or the “Company”) an innovative, leading women’s healthcare company, announced today that it received an additional $7 million private investment in the Company’s Series A Preferred Stock from Rubric Capital Management LP. TherapeuticsMD expects to use the proceeds from the transaction for working capital.
Oct 03, 2022 06:50 am ET
TherapeuticsMD Announces $7 Million Private Placement
TherapeuticsMD, Inc. (NASDAQ: TXMD), (“TherapeuticsMD” or the “Company”) an innovative, leading women’s healthcare company, announced today that it received a $7 million private investment in the Company’s Series A Preferred Stock from Rubric Capital Management LP (“Rubric”). TherapeuticsMD expects to use the proceeds from the transaction for working capital.
Sep 12, 2022 06:50 am ET
TherapeuticsMD Appoints Dr. Brian Bernick and Mr. Mark Glickman as Interim Co-Chief Executive Officers
TherapeuticsMD, Inc. (NASDAQ: TXMD), (“TherapeuticsMD” or the “Company”) an innovative, leading women’s healthcare company, announced today the appointment of Dr. Brian Bernick and Mr. Mark Glickman as the Company’s Interim Co-Chief Executive Officers and Co-Principal Executive Officers. Dr. Bernick and Mr. Glickman succeed Mr. Hugh O’Dowd as the Company’s Chief Executive Officer.
Aug 15, 2022 06:50 am ET
TherapeuticsMD Announces Second Quarter 2022 Financial Results
TherapeuticsMD, Inc. (“TXMD” or the “Company”) (NASDAQ: TXMD), an innovative, leading women’s healthcare company, today reported financial results for the Second Quarter ended June 30, 2022.
Aug 08, 2022 06:50 am ET
TherapeuticsMD to Report Second Quarter 2022 Financial Results on August 15, 2022
TherapeuticsMD, Inc. (“TXMD” or the “Company”) (NASDAQ: TXMD), an innovative, leading women’s healthcare company, today announced that it will report its second quarter 2022 financial results on Monday, August 15, 2022, at 8:30 a.m. ET prior the opening of the U.S. financial markets.
Aug 01, 2022 06:50 am ET
TherapeuticsMD Secures $15 Million Equity Investment from Rubric Capital
TherapeuticsMD, Inc. (NASDAQ: TXMD), (“TherapeuticsMD” or the “Company”) an innovative, leading women’s healthcare company, announced today that it has received a $15 million private investment in the Company’s common stock and a new series of preferred stock (“PIPE”) from Rubric Capital Management LP (“Rubric”). TherapeuticsMD expects to use the proceeds from the transaction to fulfill its near-term operating capital requirements.
Jul 13, 2022 06:50 am ET
TherapeuticsMD Announces Expiration of Tender Offer
TherapeuticsMD, Inc. (NASDAQ: TXMD), (“TXMD” or the “Company”) an innovative, leading women’s healthcare company, announced today that Athene Merger, Inc., an affiliate of EW Healthcare Partners (“EW”), did not acquire the required majority of shares of TXMD through the previously announced tender offer by the extended offer deadline of one minute after 11:59 PM Eastern Time on July 12, 2022. As a result, the tender offer has expired according to its terms. The Company anticipates that the Merger Agreement between TXMD and EW will be terminated pursuant to its terms following 11:59 PM Eastern
Jun 06, 2022 04:05 pm ET
EW Healthcare Partners Announces Commencement of the Tender Offer for All Outstanding Shares of TherapeuticsMD
NEW YORK, June 6, 2022 /PRNewswire/ -- EW Healthcare Partners (together with its consolidated subsidiaries and affiliates "EW") announced today that its affiliate, Athene Merger Sub, Inc. ("Purchaser"), commenced the previously announced cash tender offer for all of the issued and outstanding shares of common stock of TherapeuticsMD, Inc. (Nasdaq: TXMD) ("TXMD" or the "Company") at a price of $10.00 per share, net to the seller, in cash, without interest and less applicable withholding taxes. The tender offer is being made pursuant to the merger agreement (the "Merger Agreement") executed on
Jun 06, 2022 09:00 am ET
SHAREHOLDER UPDATE: Halper Sadeh LLP Investigates VMW, TPTX, CTT, TXMD
NEW YORK, June 6, 2022 /PRNewswire/ -- Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Jun 02, 2022 12:48 pm ET
THERAPEUTICSMD ALERT: Bragar Eagel & Squire, P.C. Investigates Merger of TXMD and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the officers or directors of TherapeuticsMD, Inc. (NASDAQ: TXMD) breached their fiduciary duties or violated the federal...
Jun 01, 2022 08:30 am ET
Thinking about buying stock in Tonix Pharmaceuticals, View, vTv Therapeutics, TherapeuticsMD, or Cassava Sciences?
NEW YORK, June 1, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for TNXP, VIEW, VTVT, TXMD, and SAVA.
Jun 01, 2022 12:31 am ET
Investor Alert - The M&A Class Action Firm Announces an Investigation of TherapeuticsMD, Inc. - TXMD
NEW YORK, June 1, 2022 /PRNewswire/ -- Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the "M&A Class Action Firm"), a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating TherapeuticsMD, Inc. (TXMD), relating to its proposed acquisition via a tender offer by an affiliate of EW Healthcare Partners. Under the terms of the agreement, TXMD shareholders will receive $10.00 in cash per share they own. Click here
May 31, 2022 10:30 pm ET
SHAREHOLDER UPDATE: Halper Sadeh LLP Investigates CTT, TXMD, MAAQ, GIAC
NEW YORK , May 31, 2022 /PRNewswire/ -- Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
May 31, 2022 07:34 pm ET
THERAPEUTICSMD INVESTOR ALERT by The Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of TherapeuticsMD, Inc. - TXMD
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of TherapeuticsMD, Inc. (NasdaqGS: TXMD) to an affiliate of EW Healthcare Partners. Under the terms of the proposed transaction, shareholders of TherapeuticsMD will receive only $10.00 in cash for each share of TherapeuticsMD that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
May 31, 2022 06:10 pm ET
SHAREHOLDER ALERT: Weiss Law Investigates TherapeuticsMD, Inc.
NEW YORK, May 31, 2022 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of TherapeuticsMD, Inc. ("TherapeuticsMD" or the "Company") (NASDAQ: TXMD), in connection with the proposed acquisition of the Company via a tender offer by funds managed by an affiliate of EW Healthcare Partners.  Under the terms of the merger agreement, the Company's shareholders will receive $10.00 in cash for each share of TherapeuticsMD common stock owned.  The transaction is valued at approximately $177 million.
May 31, 2022 12:35 pm ET
TXMD Alert: Monsey Firm of Wohl & Fruchter LLP Investigating Acquisition of TherapeuticsMD by EW Healthcare Partners
The law firm of Wohl & Fruchter LLP is investigating whether the directors of TherapeuticsMD (ticker: TXMD) (“TXMD”) acted in the best interests of TXMD shareholders in approving the sale of TXMD to EW Healthcare Partners (“EWHP”) for $10.00 per...
May 31, 2022 11:19 am ET
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: TherapeuticsMD, Inc. (Nasdaq - TXMD), CatchMark Timber Trust, Inc. (NYSE - CTT), Yamana Gold Inc. (NYSE - AUY),
Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ([email protected]) or Marc Ackerman ([email protected]) at 855-576-4847. There is no...
May 31, 2022 10:19 am ET
Shareholder Alert: Ademi LLP investigates whether TherapeuticsMD, Inc. has obtained a Fair Price in its transaction with EW Healthcare
MILWAUKEE, May 31, 2022 /PRNewswire/ -- Ademi LLP is investigating TherapeuticsMD (NASDAQ: TXMD) for possible breaches of fiduciary duty and other violations of law in its transaction with EW Healthcare. 
May 31, 2022 10:09 am ET
TXMD Stock Alert: Halper Sadeh LLP Is Investigating Whether the Sale of TherapeuticsMD, Inc. Is Fair to Shareholders
Halper Sadeh LLP, an investor rights law firm, is investigating whether the sale of TherapeuticsMD, Inc. (NASDAQ: TXMD) to an affiliate of EW Healthcare Partners for $10.00 per share is fair to TherapeuticsMD shareholders.
May 31, 2022 08:30 am ET
Thinking about buying stock in TherapeuticsMD, AMC Entertainment, Yamana Gold, Eledon Pharmaceuticals, or New Oriental Education?
NEW YORK, May 31, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for TXMD, AMC, AUY, ELDN, and EDU.
May 31, 2022 06:00 am ET
 TherapeuticsMD and EW Healthcare Partners Announce Definitive Agreement for EW Healthcare Partners to acquire TherapeuticsMD
TherapeuticsMD, Inc. (NASDAQ: TXMD) (“TherapeuticsMD,” “TXMD” or the “Company”), an innovative, leading women’s healthcare company, today announced that it has entered into a definitive merger agreement to be acquired by an affiliate of EW Healthcare Partners, a private equity firm dedicated to making investments in rapidly growing healthcare companies.
May 20, 2022 09:43 am ET
TherapeuticsMD Receives U.S. Food and Drug Administration (FDA) Approval for Supplemental New Drug Application (sNDA) for ANNOVERA®
TherapeuticsMD, Inc. (NASDAQ:TXMD) (“TXMD” or the “Company”), an innovative, leading women’s healthcare company, today announced the FDA’s approval of a supplemental New Drug Application (sNDA) for ANNOVERA. The sNDA included minor revisions to ANNOVERA’s in vitro release testing specification that allowed for normal manufacturing variability.
May 16, 2022 04:05 pm ET
TherapeuticsMD Announces First Quarter 2022 Financial Results
TherapeuticsMD, Inc. (“TXMD” or the “Company”) (NASDAQ: TXMD), an innovative, leading women’s healthcare company, today reported financial results for the first quarter ended March 31, 2022.
May 10, 2022 04:05 pm ET
TherapeuticsMD to Report First Quarter 2022 Financial Results on May 16, 2022
TherapeuticsMD, Inc. (“TXMD” or the “Company”) (NASDAQ: TXMD), an innovative, leading women’s healthcare company, today announced that it will report its first quarter 2022 financial results on Monday, May 16, 2022, after the closing of the U.S. financial markets.
Apr 14, 2022 04:15 pm ET
TherapeuticsMD Completes the Divestiture of vitaCare Prescription Services to GoodRx in a Cash Transaction Valued at $150 Million
TherapeuticsMD, Inc. (NASDAQ: TXMD), (“TXMD” or the “Company”) an innovative, leading women’s healthcare company, announced today the closing of the divestiture of vitaCare Prescription Services to GoodRx (NASDAQ: GDRX), in a cash transaction valued at $150 million, subject to a working capital adjustment. The Company previously announced the signing of a definitive agreement on March 6, 2022. TherapeuticsMD remains eligible to receive an additional $7 million in cash consideration contingent on vitaCare’s financial performance through 2023. With this divestiture, TherapeuticsMD streamlines it
Mar 10, 2022 06:50 am ET
TherapeuticsMD Announces Fourth Quarter 2021 Financial Results
TherapeuticsMD, Inc. (“TXMD” or the “Company”) (NASDAQ: TXMD), an innovative, leading women’s healthcare company, today reported financial results for the fourth quarter ended December 31, 2021.
Mar 07, 2022 08:31 am ET
Thinking about buying stock in Indonesia Energy, TherapeuticsMD, Cornerstone Building Brands, Vermilion Energy, or US Well Services?
NEW YORK, March 7, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for INDO, TXMD, CNR, VET, and USWS.
Mar 07, 2022 07:40 am ET
TherapeuticsMD Enters Into a Definitive Agreement to Divest vitaCare to GoodRx
TherapeuticsMD, Inc. (“TXMD” or the “Company”) (NASDAQ: TXMD), an innovative, leading women’s healthcare company, today announced that it has entered into a definitive agreement to divest its vitaCare Prescription Services (vitaCare) business to GoodRx (Nasdaq: GDRX), a consumer-focused digital healthcare platform. VitaCare is a technology and services platform that helps patients navigate key access and adherence barriers for brand medications.
Mar 01, 2022 04:30 pm ET
TherapeuticsMD to Report Fourth Quarter 2021 Financial Results on March 10, 2022
TherapeuticsMD, Inc. (“TXMD” or the “Company”) (NASDAQ: TXMD), an innovative, leading women’s healthcare company, today announced that it will report its fourth quarter 2021 financial results on Thursday, March 10, 2022, before the opening of the U.S. financial markets.
Jan 05, 2022 08:31 am ET
Thinking about buying stock in 9 Meters Biopharma, TherapeuticsMD, Cameco Corp, Nikola Corp, or Comstock Mining?
NEW YORK, Jan. 5, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NMTR, TXMD, CCJ, NKLA, and LODE.
Jan 04, 2022 09:46 am ET
Thinking about buying stock in Genprex, TherapeuticsMD, Soligenix, Norwegian Cruise Line, or Zomedica?
NEW YORK, Jan. 4, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for GNPX, TXMD, SNGX, NCLH, and ZOM.
Dec 10, 2021 04:30 pm ET
U.S. Food and Drug Administration (FDA) Responds to Request From TherapeuticsMD to Revise Certain Manufacturing Testing Limits for ANNOVERA®
TherapeuticsMD, Inc. (NASDAQ:TXMD) (“TXMD” or the “Company”), an innovative, leading women’s healthcare company, today announced that the FDA determined that it could not approve revisions to certain manufacturing testing limits for ANNOVERA through the sNDA previously submitted by the Company. In its complete response letter, the FDA provided recommendations and requested additional information that could support approval of revisions to certain manufacturing testing limits. The Company will continue to manufacture and supply ANNOVERA under the existing approved specifications.
Dec 08, 2021 06:50 am ET
TherapeuticsMD Settles U.S. Patent Litigation with Amneal for BIJUVA® (Estradiol and Progesterone) — Allowing for a May 25, 2032 Generic Entry Date
TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative, leading women’s healthcare company, today announced the settlement of the previously disclosed U.S. patent litigation for BIJUVA® with Amneal Pharmaceuticals, Inc., Amneal Pharmaceuticals, LLC, and Amneal Pharmaceuticals of New York LLC (collectively “Amneal”).
Nov 11, 2021 06:50 am ET
 TherapeuticsMD Announces Third Quarter 2021 Financial Results
TherapeuticsMD, Inc. (“TXMD” or the “Company”) (NASDAQ: TXMD), an innovative, leading women’s healthcare company, today reported financial results for the third quarter ended September 30, 2021. In addition, today the Company announced a significant cost savings initiative designed to reduce its annual costs in 2022 by at least $40 million. This figure does not include savings from, or the costs associated with, the divestiture of vitaCare, which are estimated at approximately $20 million annually.
Nov 11, 2021 06:45 am ET
TherapeuticsMD Announces Leadership Changes; Appointment of Industry Veteran, Hugh O’Dowd, as Chief Executive Officer
TherapeuticsMD, Inc. (NASDAQ: TXMD) (TXMD or the Company), an innovative, leading women’s healthcare company, today announced key leadership changes, including the appointment of Hugh O’Dowd, the Company’s current President, as the Company’s Chief Executive Officer and member of the board of directors. Mr. O’Dowd will succeed Robert G. Finizio, the Company’s Co-founder and current Chief Executive Officer, effective on or before December 31, 2021. Mr. Finizio will continue with the Company and has been appointed Vice Chair of the Board of Directors.
Oct 27, 2021 05:00 pm ET
TherapeuticsMD to Report Third Quarter 2021 Results on November 11, 2021
TherapeuticsMD, Inc. (NASDAQ: TXMD) (“TXMD” or the “Company”), an innovative, leading women’s healthcare company, today announced that it will report its third quarter 2021 financial results on Thursday, November 11, 2021, before the opening of the U.S. financial markets.
Oct 15, 2021 05:33 pm ET
TherapeuticsMD Announces Appointment of Mark Glickman as Chief Business Officer
TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative, leading women’s healthcare company, today announced the appointment of Mark Glickman as the Company’s Chief Business Officer.
Sep 02, 2021 06:50 am ET
Therapeutics MD Is Urging Women to ‘Take Pause’ During Menopause Awareness Month
This September, TherapeuticsMD, Inc., an innovative women’s healthcare company (NASDAQ: TXMD), is recognizing Menopause Awareness Month, as it aims to empower the 64 million women in the U.S. currently in menopauseii. To celebrate this month and all menopausal women, TherapeuticsMD encourages people to Take Pause and learn about menopause.
Aug 23, 2021 06:50 am ET
TherapeuticsMD Announces Issuance of a J-Code for ANNOVERA® to Be Utilized in the Public Health Sector
TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative, leading women’s healthcare company, today announced that the Centers for Medicare and Medicaid Services (CMS) confirmed its preliminary recommendation to assign a permanent product-specific Healthcare Common Procedure Coding System (HCPCS) J Code for ANNOVERA (segesterone acetate and ethinyl estradiol vaginal system). As a result, CMS established the new HCPCS Level II code J7294 “Segesterone acetate and ethinyl estradiol 0.15mg, 0.013mg per 24 hours; yearly vaginal system, each,” which will allow Title X facilities to be reimbursed for dispe
Aug 09, 2021 04:30 pm ET
TherapeuticsMD Announces Appointment of Hugh O’Dowd as President
TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative, leading women’s healthcare company, today announced the appointment of Hugh O’Dowd as President. Mr. O’Dowd succeeds John C.K. Milligan, IV, who the Company recently appointed as Chief Executive Officer of its vitaCare Prescription Services business.
Aug 04, 2021 06:50 am ET
TherapeuticsMD Announces Second Quarter 2021 Financial Results
TherapeuticsMD, Inc. (“TXMD” or the “Company”) (NASDAQ: TXMD), an innovative, leading women’s healthcare company, today reported financial results for the second quarter ended June 30, 2021.
Jul 26, 2021 06:50 am ET
TherapeuticsMD to Report Second Quarter 2021 Results on August 4, 2021
TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative, leading women’s healthcare company, today announced that it will report its second quarter 2021 financial results on Wednesday, August 4, 2021, before the opening of the U.S. financial markets. Following the announcement, executive management will host a conference call and webcast at 8:30 a.m. ET to discuss the Company’s financial results and provide a business update.
May 25, 2021 06:50 am ET
TherapeuticsMD Announces Submission of Low Dose BIJUVA® 0.5 mg/100 mg Supplemental New Drug Application to FDA
TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative, leading women’s healthcare company, announced today that the Company submitted a supplemental New Drug Application (“sNDA”) for BIJUVA (estradiol and progesterone) capsules, 0.5 mg/100 mg, to the U.S. Food and Drug Administration (“FDA”).
May 24, 2021 07:00 am ET
The Sun Sentinel Names TherapeuticsMD, Inc. a Winner of the South Florida Top Workplaces 2021 Award
TherapeuticsMD, Inc. (NASDAQ: TXMD), has been awarded a Top Workplaces 2021 honor by The Sun Sentinel. The list is based solely on employee feedback gathered through a third-party survey administered by employee engagement technology partner
May 06, 2021 07:00 am ET
TherapeuticsMD Announces First Quarter 2021 Financial Results
TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative, leading women’s healthcare Company, today reported financial results for the first quarter ended March 31, 2021.
May 03, 2021 07:00 am ET
TherapeuticsMD Announces Poster Presentation of ANNOVERA® Data at the American College of Obstetricians and Gynecologists 2021 Annual Meeting
TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women’s healthcare company, today announced Phase 3 menstrual bleeding profile data for ANNOVERA (segesterone acetate and ethinyl estradiol vaginal system) was presented at the 2021 American College of Obstetricians and Gynecologists (ACOG) Annual Clinical and Scientific Meeting conducted virtually from April 30 to May 2, 2021.
Apr 29, 2021 07:00 am ET
TherapeuticsMD to Report First Quarter 2021 Results on May 6, 2021
TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women’s healthcare company, today announced that it will report its first quarter 2021 financial results on Thursday, May 6, 2021, before the opening of the U.S. financial markets. Following the announcement, executive management will host a conference call and webcast at 8:30 a.m. ET on such date to discuss the Company’s financial results and provide a business update.
Apr 08, 2021 04:05 pm ET
TherapeuticsMD and Theramex Announce the Approval of BIJUVE® Capsules Indicated for Hormone Replacement Therapy in the United Kingdom and Under the Trade Name BIJUVA® in Belgium
TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative, leading women’s healthcare company, and Theramex, a dedicated women’s health company, announced that BIJUVE® has received approval from the Medicines and Healthcare products Regulatory Agency (MHRA) for use in the United Kingdom and, from the Federal Agency for Medicines and Health Products (FAMHP) for use in Belgium under BIJUVA®.
Mar 02, 2021 07:00 am ET
TherapeuticsMD Announces Fourth Quarter and Full-Year 2020 Financial Results
TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative, leading women’s healthcare company, today reported financial results for the full-year and fourth quarter ended December 31, 2020 and provided a business update.
Mar 01, 2021 07:00 am ET
TherapeuticsMD Announces Participation in Upcoming Investor Conferences
TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women’s healthcare company, today announced that the company will participate at the following investor conferences:
Feb 23, 2021 04:05 pm ET
TherapeuticsMD to Report Fourth Quarter 2020 Results on March 2, 2021
TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women’s healthcare company, today announced that it will report its fourth quarter 2020 financial results on Tuesday, March 2, 2021, before the opening of the U.S. financial markets. Following the announcement, executive management will host a conference call and webcast at 8:30 a.m. ET on such date to discuss the Company’s financial results and provide a business update.
Feb 16, 2021 04:01 pm ET
TherapeuticsMD Announces Closing of its Underwritten Public Offering of Common Stock
TherapeuticsMD, Inc. (NASDAQ:TXMD) today announced the closing of its underwritten public offering of 59,459,460 shares of its common stock for net proceeds of approximately $97.1 million, after deducting underwriting discounts and commissions and estimated offering expenses payable by TherapeuticsMD. All of the shares in the offering were sold by TherapeuticsMD. In addition, TherapeuticsMD has granted the underwriter a 30-day option to purchase up to approximately 8.9 million additional shares of common stock.
Feb 11, 2021 09:02 am ET
TherapeuticsMD Announces Pricing of $110 Million Public Offering of Common Stock
TherapeuticsMD, Inc. (NASDAQ:TXMD) today announced the pricing of its underwritten public offering of approximately 59.5 million shares of its common stock for gross proceeds of $110 million, before deducting the underwriting discounts and commissions and other estimated offering expenses payable by TherapeuticsMD. The offering is expected to close on or about February 16, 2021, subject to customary closing conditions. In addition, TherapeuticsMD has granted the underwriter a 30-day option to purchase up to approximately 8.9 million additional shares of common stock.
Feb 10, 2021 04:01 pm ET
TherapeuticsMD Announces Underwritten Public Offering of its Common Stock
TherapeuticsMD, Inc. (NASDAQ:TXMD) today announced an underwritten public offering of its common stock. The Company has granted the underwriter a 30-day option to purchase up to an additional 15% of the number of shares of its common stock offered in the offering. All of the shares in the offering are to be sold by TherapeuticsMD.
Feb 08, 2021 07:30 am ET
Thinking about buying stock in Ocugen, Westport Fuel Systems, Purple Biotech, TherapeuticsMD, or Veru?
NEW YORK, Feb. 8, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for OCGN, WPRT, PPBT, TXMD, and VERU.
Dec 29, 2020 07:00 am ET
TherapeuticsMD Announces Participation in Upcoming Investor Conferences
TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women’s healthcare company, today announced that the company will participate at the following investor conferences:
Dec 15, 2020 08:13 am ET
Comedian Whitney Cummings Partners with TherapeuticsMD to Launch “Just Say Vagina”
TherapeuticsMD, Inc. (NASDAQ:TXMD), an innovative women’s healthcare company, announced the launch of Just Say Vagina to encourage women to speak clearly and directly about their reproductive health. Comedian Whitney Cummings will discuss her journey from serial apologizer to an unapologetic role model who no longer uses euphemisms or apologi
Nov 13, 2020 04:05 pm ET
TherapeuticsMD Announces Closing of its Underwritten Public Offering of Common Stock
TherapeuticsMD, Inc. (NASDAQ:TXMD) today announced the closing of its underwritten public offering of 23,437,500 shares of its common stock for net proceeds of approximately $27.5 million, after deducting underwriting discounts and commissions and estimated offering expenses payable by TherapeuticsMD. All of the shares in the offering were sold by TherapeuticsMD.
Nov 13, 2020 07:00 am ET
TherapeuticsMD Announces Participation in the Stifel 2020 Virtual Healthcare Conference
TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women’s healthcare company, today announced that the company will participate in the Stifel 2020 Virtual Healthcare Conference.
Nov 10, 2020 08:58 am ET
TherapeuticsMD Announces Pricing of $30 Million Public Offering of Common Stock
TherapeuticsMD, Inc. (NASDAQ:TXMD) today announced the pricing of its underwritten public offering of approximately 23.4 million shares of its common stock for gross proceeds of $30 million, before deducting the underwriting discounts and commissions and other estimated offering expenses payable by TherapeuticsMD. The offering is expected to close on or about November 12, 2020, subject to customary closing conditions. In addition, TherapeuticsMD has granted the underwriter a 30-day option to purchase up to approximately 3.5 million additional shares of common stock.
Nov 09, 2020 04:01 pm ET
TherapeuticsMD Announces Underwritten Public Offering of its Common Stock
TherapeuticsMD, Inc. (NASDAQ:TXMD) today announced an underwritten public offering of its common stock. The Company has granted the underwriter a 30-day option to purchase up to an additional 15% of the number of shares of its common stock offered in the offering. All of the shares in the offering are to be sold by TherapeuticsMD.
Nov 09, 2020 06:55 am ET
TherapeuticsMD® Announces Third Quarter 2020 Financial Results
TherapeuticsMD, Inc. (NASDAQ:TXMD), an innovative, leading women’s healthcare company, today reported financial results for the third quarter ended September 30, 2020.
Oct 29, 2020 07:00 am ET
TherapeuticsMD to Report Third Quarter 2020 Results on November 9, 2020
TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women’s healthcare company, today announced that it will report its third quarter 2020 financial results on Monday, November 9, 2020, before the opening of the U.S. financial markets. Following the announcement, executive management will host a conference call and webcast at 8:30 a.m. ET on such date to discuss the Company’s financial results and provide a business update.
Oct 26, 2020 04:05 pm ET
POPSUGAR Launches New Women’s Health Destination, “Full Disclosure,” in Collaboration With TherapeuticsMD
POPSUGAR, the #1 most engaged-with Women’s Lifestyle site in the U.S., together with TherapeuticsMD Inc. (NASDAQ: TXMD), launched its new women’s health destination, “Full Disclosure,” utilizing POPSUGAR’s expertise in educational, informative, and approachable health content to promote ANNOVERA® (segesterone acetate and ethinyl estradiol vaginal system), a first of its kind annual vaginal birth control ring. ANNOVERA is the only FDA-approved long-lasting birth control method that does not require a medical procedure.
Oct 09, 2020 08:00 am ET
TherapeuticsMD Supports the Importance of Empowering Women to Make Informed Choices about their Sexual and Reproductive Health
TherapeuticsMD, Inc. (NASDAQ:TXMD), an innovative women’s healthcare company, is proud to reinforce the importance of empowering women to make informed choices about their sexual and reproductive health, in consultation with their healthcare provider.
Sep 25, 2020 09:02 am ET
TherapeuticsMD Provides Update on Third Quarter Progress
TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women’s healthcare company, today announced that the Company is on track to meet or exceed third quarter 2020 total net revenue consensus of $15.1 million. For the Company’s ANNOVERA (segesterone acetate and ethinyl estradiol vaginal system) product, the Company has seen increases in orders to wholesalers, retail pharmacies and online distributors throughout the quarter that are greater than the patient demand numbers being reported by industry prescription tracking databases. In addition, weekly inventory on hand reported by wholes
Sep 21, 2020 05:01 pm ET
Knight and TherapeuticsMD Announce Health Canada Approval of BIJUVA®
Knight Therapeutics Inc. (TSX: GUD) (“Knight”) and TherapeuticsMD, Inc. (NASDAQ: TXMD) (“TherapeuticsMD”) announced today the approval of BIJUVA® (estradiol and progesterone) capsules by Health Canada. In Canada, BIJUVA is indicated for the...
Sep 21, 2020 05:01 pm ET
Knight and TherapeuticsMD Announce Health Canada Approval of BIJUVA®
Knight Therapeutics Inc. (TSX: GUD) (“Knight”) and TherapeuticsMD, Inc. (NASDAQ: TXMD) (“TherapeuticsMD”) announced today the approval of BIJUVA® (estradiol and progesterone) capsules by Health Canada. In Canada, BIJUVA is indicated for the treatment of moderate to severe vasomotor symptoms (VMS) associated with menopause in women with an intact uterus. VMS are commonly known as hot flashes or flushes and night sweats. VMS affect 60% to 80% of women entering menopause.1
Sep 10, 2020 06:50 am ET
TherapeuticsMD Announces Participation at Two Upcoming Virtual Investor Conferences
TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women’s healthcare company, today announced that the company will participate in two upcoming virtual investor conferences. Chief Executive Officer Robert G. Finizio will provide an overview of the company at the conferences.
Sep 09, 2020 04:05 pm ET
TherapeuticsMD Announces Patent Updates for ANNOVERA®
TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women’s healthcare company, today announced patent updates for ANNOVERA (segesterone acetate and ethinyl estradiol vaginal system), the first and only long-lasting, patient-controlled, procedure-free, reversible prescription contraceptive option for women. On September 8, 2020, the United States Patent and Trademark Office (USPTO) issued its second ANNOVERA patent (U.S. Patent No. 10,765,628) that can be listed in the U.S. Food and Drug Administration’s (FDA) Approved Drug Products with Therapeutic Equivalence Evaluations (commonly
Aug 25, 2020 07:30 am ET
Knight and TherapeuticsMD Announce Health Canada Approval of IMVEXXY®
Knight Therapeutics Inc. (TSX: GUD) (“Knight”) and TherapeuticsMD, Inc. (NASDAQ: TXMD) (“TherapeuticsMD”) announced today the approval of IMVEXXY® by Health Canada. In Canada, IMVEXXY is for the treatment of postmenopausal moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy (VVA). VVA is a prevalent, chronic, and progressive condition associated with menopause. Common symptoms of VVA include dryness, discomfort, and pain in the vaginal and vulvar areas1-4. IMVEXXY is an applicator-free, estradiol softgel vaginal capsule indicated for postmenopausal wom
Aug 06, 2020 06:50 am ET
TherapeuticsMD® Announces Second Quarter 2020 Financial Results
TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative, leading women’s healthcare company, today reported financial results for the second quarter ended June 30, 2020.
Jul 29, 2020 06:50 am ET
TherapeuticsMD to Report Second Quarter 2020 Results on August 6, 2020
TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women’s healthcare company, today announced that it will report its second quarter 2020 financial results on Thursday, August 6, 2020, before the opening of the U.S. financial markets. Following the announcement, executive management will host a conference call and webcast at 8:30 a.m. ET on such date to discuss the Company’s financial results and provide a business update.
Jul 15, 2020 06:50 am ET
TherapeuticsMD and Nurx Expand Access to ANNOVERA®
TherapeuticsMD, an innovative women’s healthcare company, and Nurx, the largest online practice for women’s health, today announced an arrangement to expand access to ANNOVERA® (segesterone acetate and ethinyl estradiol vaginal system), a first of its kind annual birth control ring. ANNOVERA is the first FDA-approved long-lasting birth control method that does not require a medical procedure. At a time when women are facing significant barriers to reproductive healthcare, this arrangement will greatly expand access to this highly effective and innovative form of contraception to Nur
Jun 01, 2020 06:50 am ET
TherapeuticsMD Announces Appointment of James C. D’Arecca as Chief Financial Officer and Retirement of Daniel A. Cartwright as Chief Financial Officer
TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women’s healthcare company, announced today the appointment of James C. D’Arecca as the Company’s Chief Financial Officer, effective June 1, 2020. Mr. D’Arecca succeeds Daniel A. Cartwright, who has retired from his position as the Company’s Chief Financial Officer, also effective June 1, 2020. Mr. Cartwright will remain with the Company as an advisor for a transitional period. Mr. D’Arecca joins TherapeuticsMD with broad experience in corporate and operational finance, most recently as Senior Vice President and Chief Accounting Officer of All
May 08, 2020 06:50 am ET
 TherapeuticsMD Announces Participation at the BofA Securities 2020 Health Care Conference
TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women’s healthcare company, today announced that the company will participate in the BofA Securities 2020 Health Care Conference being held virtually. Chief Executive Officer Robert G. Finizio will provide an overview of the company at the conference.
May 06, 2020 06:50 am ET
TherapeuticsMD Announces First Quarter 2020 Financial Results
TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative, leading women’s healthcare Company, today reported financial results for the first quarter ended March 31, 2020.
Apr 30, 2020 09:31 am ET
Thinking about buying stock in Centennial Resource Development, Chimerix, TherapeuticsMD, Pennsylvania Real Estate, or American Airlines?
NEW YORK, April 30, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CDEV, CMRX, TXMD, PEI, and AAL.
Apr 29, 2020 06:50 am ET
TherapeuticsMD Announces Issuance of First Orange Book Listable U.S. Patent for ANNOVERA®
TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women’s healthcare company, today announced that the United States Patent and Trademark Office (USPTO) has issued a patent that covers the labeled indication for ANNOVERA® (segesterone acetate and ethinyl estradiol vaginal system), the first and only long-lasting, patient-controlled, procedure-free, reversible prescription contraceptive option for women. TherapeuticsMD has 30 days to submit the formal paperwork to have this patent listed in the U.S. Food and Drug Administration’s (FDA) Approved Drug Products with Therapeutic Equival
Apr 28, 2020 06:50 am ET
TherapeuticsMD to Report First Quarter 2020 Results on May 6, 2020
TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women’s healthcare company, today announced that it will report its first quarter 2020 financial results on Wednesday, May 6, 2020, before the opening of the U.S. financial markets. Following the announcement, executive management will host a conference call and webcast at 8:30 a.m. ET on such date to discuss the Company’s financial results and provide a business update.
Apr 22, 2020 06:50 am ET
TherapeuticsMD Further Strengthens Board with Appointment of New Independent Director
On behalf of the Board of Directors of TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative, leading women’s healthcare company, Chairman Tommy G. Thompson today announced the appointment of Karen L. Ling to the Company’s Board of Directors.
Mar 26, 2020 04:05 pm ET
TherapeuticsMD Provides COVID-19-Related Business Update
TherapeuticsMD, Inc. (NASDAQ: TXMD) (“TherapeuticsMD” or the “Company”), an innovative, leading women’s healthcare company, today provided an update on its operations in response to the continued spread of COVID-19 (coronavirus) pandemic. The Company has developed a comprehensive COVID-19 contingency plan designed to preserve the value of the Company’s investments in its sales and marketing infrastructure, protect the Company’s balance sheet during this period of market disruption, and meet the needs of the Company’s patients and prescribers.
Mar 24, 2020 07:45 am ET
TherapeuticsMD Strengthens Board with Appointment of Industry Leaders
On behalf of the Board of Directors of TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative, leading women’s healthcare company, Chairman Tommy G. Thompson today announced the appointments of Paul Bisaro and Gail Naughton, Ph.D., to the Company’s Board of Directors. The appointments fill two of the vacancies created by the resignations from the Board of Brian Bernick, M.D., John C.K. Milligan, IV and Nicholas Segal. Dr. Bernick will continue to serve as a Co-Founder of TherapeuticsMD on a full-time basis, supporting the Company’s outreach with healthcare providers. Mr. Milligan will continue to
Mar 16, 2020 06:00 am ET
TherapeuticsMD Provides Business Update on COVID-19 Pandemic
TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women’s healthcare company, today provided an update on its business operations as the COVID-19 situation evolves. At this time, TherapeuticsMD continues to provide an uninterrupted supply of its portfolio of products for patients. The company has activated virtual options to ensure business continuity. In addition, the company has taken action to support the health of its employees. While TherapeuticsMD cannot predict the extent to which COVID-19 pandemic will continue to spread and how it will impact society and business, the company will co
Feb 27, 2020 07:00 am ET
TherapeuticsMD Announces Participation at the Cowen 40th Annual Healthcare Conference
TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women’s healthcare company, today announced that the company will participate in the Cowen 40th Annual Healthcare Conference in Boston. Chief Executive Officer Robert G. Finizio will provide an overview of the company at the conference.
Feb 20, 2020 06:57 am ET
TherapeuticsMD Announces Fourth Quarter and Full-Year 2019 Financial Results
TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative, leading women’s healthcare company, today reported financial results for the full-year and fourth quarter ended December 31, 2019 and provided 2020 financial guidance.
Feb 13, 2020 06:30 am ET
TherapeuticsMD and Afaxys Enter Into Agreement to Expand Access to ANNOVERA® in the U.S. Public Health Sector
TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women’s healthcare company, and Afaxys Pharma, LLC, a pharmaceutical company focused on serving women in the public health system, announced today that they have entered into an agreement to expand access to ANNOVERA® (segesterone acetate and ethinyl estradiol vaginal system) in the United States public health sector. The arrangement combines Afaxys' unique experience and capabilities serving the United States public health contraception market with TherapeuticsMD’s commitment to supply ANNOVERA to the United States public health system
Feb 10, 2020 06:30 am ET
TherapeuticsMD to Report Fourth Quarter 2019 Results on February 20, 2020
TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women’s healthcare company, today announced that it will report its fourth quarter 2019 financial results on Thursday, February 20, 2020, before the opening of the U.S. financial markets. Following the announcement, executive management will host a conference call and webcast at 8:30 a.m. ET on such date to discuss the Company’s financial results and provide a business update.
Feb 03, 2020 06:30 am ET
TherapeuticsMD Announces Submission of New Drug Application Prior Approval Efficacy Supplement to the U.S. Food and Drug Administration for Lower Dose of BIJUVA®
TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women’s healthcare company, announced today that it submitted a New Drug Application prior-approval efficacy supplement for BIJUVA 0.5 mg/100 mg (estradiol and progesterone) capsules to the U.S. Food and Drug Administration (FDA) late January 2020.
Jan 07, 2020 06:30 am ET
TherapeuticsMD, an Innovative Women’s Healthcare Company, and PlushCare, a Virtual Health Platform, Announce Enhanced Access to Women’s Health Products
TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women’s healthcare company, and PlushCare, a virtual health platform that enables patients to book a virtual doctor’s appointment to get treatment, today announced that TherapeuticsMD’s women’s health products can be prescribed to patients via the PlushCare platform.
Jan 06, 2020 06:55 am ET
TherapeuticsMD Announces Participation at the JP Morgan Healthcare Conference
TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women’s healthcare company, today announced that the company will participate in the 38th Annual J.P. Morgan Healthcare Conference in San Francisco. Chief Executive Officer Robert G. Finizio will provide an overview of the company at the conference.
Dec 30, 2019 06:55 am ET
TherapeuticsMD Announces Amendment to Term Loan Financing Facility with TPG Sixth Street Partners
TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative, leading women’s healthcare company, today announced that the Company and TPG Sixth Street Partners (“Sixth Street”) have amended the terms of the Company’s existing term loan financing facility to revise the draw trigger for one of the two $50 million delayed draw loan tranches thereunder.
Nov 26, 2019 07:30 am ET
Knight and TherapeuticsMD Announce Filing of New Drug Submission for BIJUVA® in Canada
Knight Therapeutics Inc. (TSX: GUD) (“Knight”) and TherapeuticsMD, Inc. (NASDAQ: TXMD) (“TherapeuticsMD”) announced today that Knight's New Drug Submission (NDS) for BIJUVA® has been accepted for review by Health Canada. BIJUVA, estradiol and progesterone capsules, is licensed by Knight from TherapeuticsMD. BIJUVA is a bio-identical* hormone therapy combination of estradiol and progesterone in a single, daily oral capsule intended for the treatment of moderate-to-severe vasomotor symptoms associated with menopause in women with intact uteri.
Nov 12, 2019 07:00 am ET
TherapeuticsMD Announces Participation at the Stifel 2019 Healthcare Conference
TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women’s healthcare company, today announced that the company will participate in the Stifel 2019 Healthcare Conference in New York City. Chief Executive Officer Robert G. Finizio will provide an overview of the company at the conference.
Nov 06, 2019 04:05 pm ET
TherapeuticsMD Announces Third Quarter 2019 Financial Results
TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative, leading women’s healthcare company, today reported financial results for the third quarter ended September 30, 2019 and provided a business update.
Nov 01, 2019 04:05 pm ET
TherapeuticsMD to Report Third Quarter 2019 Results on November 6, 2019
TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women’s healthcare company, today announced that it will report its third quarter 2019 financial results on Wednesday, November 6, 2019, after the closing of the U.S. financial markets. Following the announcement, executive management will host a conference call and webcast at 4:30 p.m. ET on such date to discuss the Company’s financial results and provide a business update.
Oct 30, 2019 05:05 pm ET
Knight and TherapeuticsMD Announce Filing of New Drug Submission for Joyesta™ in Canada
Knight Therapeutics Inc. (TSX: GUD) (“Knight”) and TherapeuticsMD, Inc. (NASDAQ: TXMD) (“TherapeuticsMD”) announced today that Knight's New Drug Submission (NDS) for Joyesta™ has been accepted for review by Health Canada. Joyesta, licensed from TherapeuticsMD, is an applicator-free estradiol softgel vaginal capsule for the treatment of postmenopausal symptoms of vulvar and vaginal atrophy due to estrogen deficiency. Joyesta is marketed as IMVEXXY® (estradiol vaginal inserts) by TherapeuticsMD in the U.S., for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atro
Oct 29, 2019 04:05 pm ET
TherapeuticsMD Announces Closing of Its Underwritten Public Offering of Common Stock
TherapeuticsMD, Inc. (NASDAQ:TXMD) today announced the closing of its underwritten public offering of 29,900,000 shares of its common stock at a price to the public of $2.75 per share, inclusive of the underwriters’ option to purchase additional shares of common stock, which option was exercised in full. TherapeuticsMD received net proceeds from the offering of approximately $77.0 million, after deducting underwriting discounts and commissions and estimated offering expenses payable by TherapeuticsMD. All of the shares in the offering were sold by TherapeuticsMD.
Oct 24, 2019 07:46 pm ET
TherapeuticsMD Announces Pricing of Its Underwritten Public Offering of 26 Million Shares of Common Stock
TherapeuticsMD, Inc. (NASDAQ:TXMD) today announced the pricing of its underwritten public offering of 26,000,000 shares of its common stock at a price to the public of $2.75 per share. TherapeuticsMD has also granted to the underwriters of the offering a 30-day option to purchase up to an additional 3,900,000 shares of common stock at the public offering price, less the underwriting discount. The gross proceeds to TherapeuticsMD from the offering are expected to be $71.5 million, before deducting underwriting discounts, commissions and other offering expenses payable by TherapeuticsMD, assumin
Oct 23, 2019 04:45 pm ET
TherapeuticsMD Announces Proposed Underwritten Public Offering of 22 Million Shares of Common Stock
TherapeuticsMD, Inc. (NASDAQ:TXMD) today announced the launch of an underwritten public offering of 22,000,000 shares of its common stock. TherapeuticsMD also expects to grant the underwriters of the offering a 30-day option to purchase up to an additional 3,300,000 shares of common stock at the public offering price, less the underwriting discount. All of the shares in the offering are to be sold by TherapeuticsMD. The offering is subject to market conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Oct 23, 2019 04:41 pm ET
TherapeuticsMD Announces Estimated Third Quarter 2019 Financial Results
TherapeuticsMD, Inc. (NASDAQ: TXMD) (the “Company”) today announced its estimates of the financial results for the third quarter ended September 30, 2019.
Oct 11, 2019 07:00 am ET
TherapeuticsMD Announces Presentations on ANNOVERA™ at the 2019 Annual Meeting of the American Society for Reproductive Medicine
TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women’s healthcare company, today announced the presentation of ANNOVERA™ (segesterone acetate and ethinyl estradiol vaginal system) findings at the annual meeting of the American Society for Reproductive Medicine (ASRM) being held in Philadelphia, PA on October 12-16, 2019.
Oct 10, 2019 06:45 am ET
TherapeuticsMD Vice President of Business Development Named Finalist in 16th Annual Stevie® Awards for Women in Business
TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women’s healthcare company, today announced that Jennifer Wilson, Vice President of Business Development, has been named a Finalist in the Female Executive of the Year – Business Products category in the 16th annual Stevie® Awards for Women in Business.
Sep 26, 2019 07:00 am ET
TherapeuticsMD Announces Participation at the 2019 Cantor Healthcare Conference
TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women’s healthcare company, today announced that the company will participate in the 2019 Cantor Global Healthcare Conference in New York City. Chief Executive Officer Robert G. Finizio will provide an overview of the company at the conference.
Sep 24, 2019 07:00 am ET
TherapeuticsMD Announces Multiple Presentations Related to IMVEXXY® and BIJUVA® at the 2019 Annual Meeting of the North American Menopause Society
TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women’s healthcare company, today announced the schedule of two oral presentations and five posters that will be presented at the 2019 Annual Meeting of the North American Menopause Society (NAMS) being held on September 25-28, 2019, related to IMVEXXY® (estradiol vaginal inserts) and BIJUVA® (estradiol and progesterone capsules).
Aug 12, 2019 10:30 am ET
Cellulite Treatment Market Projected to Reach $1,438.5 Billion by 2026
PALM BEACH, Florida, Aug. 12, 2019 /PRNewswire/ -- Cellulite has been the bane of many women (and men too) for years, but the market is expected to rise significantly through 2026, industry reports project. One report said that the global cellulite treatment market size was valued at USD $273.94 million in 2018 and is expected to register a CAGR of 8.2% through 2026. Another report added that the global cellulite treatment market was valued at around US$ 619.2 Mn in 2017 and is anticipated to reach US $1,438.5 Mn by 2026, expanding at a CAGR of 10.1% from 2018 to 2026.The second report opine
Aug 06, 2019 04:05 pm ET
TherapeuticsMD Announces Second Quarter 2019 Financial Results
TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative, leading women’s healthcare company, today reported financial results for the second quarter ended June 30, 2019 and provided a business update.
Jul 25, 2019 07:00 am ET
TherapeuticsMD to Report Second Quarter 2019 Results on August 6, 2019
TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women’s healthcare company, today announced that it will report its second quarter 2019 financial results on Tuesday, August 6, 2019, after the closing of the U.S. financial markets. Following the announcement, executive management will host a conference call and webcast at 4:30 p.m. ET on such date to discuss the Company’s financial results and provide a business update.
Jun 10, 2019 07:00 am ET
TherapeuticsMD to Host Investor and Analyst Day Today
TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative, leading women’s healthcare company, will host its Investor and Analyst Day today in New York City.
Jun 07, 2019 07:15 am ET
TherapeuticsMD and Theramex Enter into Exclusive License and Supply Agreement to Commercialize BIJUVA™ and IMVEXXY® Outside the United States
TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative, leading women’s healthcare company, today announced that it has entered into an exclusive license and supply agreement with Theramex, a leading, global specialty pharmaceutical company dedicated to women’s health, to commercialize BIJUVA (estradiol and progesterone capsules) and IMVEXXY (estradiol vaginal inserts) outside of the United States. Theramex is a portfolio company of CVC Capital Partners.
May 29, 2019 07:00 am ET
TherapeuticsMD to Host Investor and Analyst Day on June 10, 2019 in New York City
TherapeuticsMD, Inc. (NASDAQ:TXMD), an innovative, leading women’s healthcare company, today announced that it will host an Investor and Analyst Day on Monday, June 10, 2019, in New York City.
May 08, 2019 07:00 am ET
TherapeuticsMD Announces Participation at the Bank of America Merrill Lynch 2019 Health Care Conference
TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative, leading women’s healthcare company, today announced that the company will participate in the Bank of America Merrill Lynch 2019 Health Care Conference. Chief Executive Officer Robert G. Finizio will provide an overview of the company at the conference.
May 06, 2019 04:05 pm ET
TherapeuticsMD Announces First Quarter 2019 Financial Results
TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative, leading women’s healthcare company, today announced its commercial and corporate update for the first quarter ended March 31, 2019.
May 06, 2019 07:00 am ET
TherapeuticsMD Presented New Research at the American College of Obstetricians and Gynecologists 2019 Annual Meeting that Explores How Women’s Menopausal Symptoms Affect Men
TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative, leading women's healthcare company, today announced the presentation of results from the Men’s Attitude Toward Menopause Survey (MATE), a large study of men’s understanding of and attitudes related to menopause, at the American College of Obstetricians and Gynecologists 2019 Annual Meeting. The data, representing insights collected from 450 men married to and living with women of menopausal age, uncovered men’s perceptions and attitudes towards menopause and their role in their partner’s menopa
May 03, 2019 07:00 am ET
TherapeuticsMD Announces Oral and Poster Presentations on BIJUVA™ and ANNOVERA™ at the American College of Obstetricians and Gynecologists 2019 Annual Meeting
TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative, leading women’s healthcare company, today announced the schedule of presentations on BIJUVATM (estradiol and progesterone capsules, 1 mg/100 mg) and ANNOVERA™ (segesterone acetate/ethinyl estradiol vaginal system) at the American College of Obstetricians and Gynecologists (ACOG) 2019 Annual Meeting in Nashville on May 3-6, 2019.
May 02, 2019 07:20 am ET
SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating TherapeuticsMD, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors
NEW YORK, May 2, 2019 /PRNewswire/ -- Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors of TherapeuticsMD, Inc. (NASDAQ: TXMD).
Apr 29, 2019 07:00 am ET
TherapeuticsMD to Report First Quarter 2019 Results on May 6, 2019
TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women’s healthcare company, today announced that it will report its first quarter 2019 financial results on Monday, May 6, 2019, after the closing of the U.S. financial markets. Following the announcement, executive management will host a conference call and webcast at 4:30 p.m. ET on such date to discuss the Company’s financial results and provide a business update.
Apr 24, 2019 04:10 pm ET
TherapeuticsMD Closes $300 Million Non-Dilutive Term Loan Financing Facility with TPG Sixth Street Partners
TherapeuticsMD, Inc. (NASDAQ:TXMD), an innovative, leading women’s healthcare company, today announced that it has closed its previously disclosed $300 million non-dilutive secured term loan financing facility with TPG Sixth Street Partners (“TSSP”), the global finance and investment business in strategic partnership with TPG, the global alternative asset firm.
Apr 17, 2019 07:05 am ET
TherapeuticsMD Signs Binding Commitment Letter for $300 Million Non-Dilutive Term Loan Financing Facility with TPG Sixth Street Partners
TherapeuticsMD, Inc. (NASDAQ:TXMD), an innovative, leading women’s healthcare company, today announced that it has signed a binding commitment letter for a fully-negotiated $300 million non-dilutive secured term loan financing facility with TPG Sixth Street Partners (“TSSP”), the global finance and investment business in strategic partnership with TPG, the global alternative asset firm.
Apr 17, 2019 07:00 am ET
TherapeuticsMD Announces Commercial Availability of BIJUVA™ in the U.S.
TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative, leading women’s healthcare company, today announced the commercial availability of BIJUVATM (estradiol and progesterone capsules, 1 mg/100 mg) in the United States. BIJUVA is the first and only FDA-approved bio-identical hormone therapy combination of estradiol and progesterone in a single, oral daily capsule for the treatment of moderate-to-severe vasomotor symptoms (commonly known as hot flashes or flushes) due to menopause in women with a uterus. BIJUVA offers a proven balance of
Mar 25, 2019 07:00 am ET
TherapeuticsMD Announces Oral and Poster Presentations on BIJUVA™ and ANNOVERA™ at the Endocrine Society 2019 Annual Meeting
TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative, leading women’s healthcare company, today announced the schedule of presentations on BIJUVA™ (estradiol and progesterone capsules, 1 mg/100 mg) and ANNOVERA™ (segesterone acetate/ethinyl estradiol vaginal system) at the Endocrine Society 2019 Annual Meeting in New Orleans, on March 23-26, 2019.
Mar 08, 2019 07:00 am ET
TherapeuticsMD Announces Oral Presentations on BIJUVA and ANNOVERA, and Poster Presentations Related to Menopause Symptoms and Treatments at 2019 ISSWSH/ISSM Joint Meeting
TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative, leading women’s healthcare company, today announced the schedule of oral presentations on clinical data for BIJUVATM (estradiol and progesterone capsules, 1 mg/100 mg) and ANNOVERATM (segesterone acetate/ethinyl estradiol vaginal system), and poster presentations related to menopause symptoms and treatments, at the International Society for the Study of Women’s Sexual Health (ISSWSH) and the International Society of Sexual Medicine (ISSM) joint annual meeting in Atl
Mar 05, 2019 08:35 am ET
Consolidated Research: 2019 Summary Expectations for TherapeuticsMD, Ensco plc, Cray, BeiGene, The Gap, and Nordson — Fundamental Analysis, Key Performance Indications
In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of TherapeuticsMD, Inc. (NASDAQ:TXMD), Ensco plc (NYSE:ESV), Cray Inc...
Feb 28, 2019 07:00 am ET
TherapeuticsMD Announces Participation in Two Upcoming Investor Conferences
TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative, leading women’s healthcare company, today announced that the company will participate in two upcoming healthcare conferences. Chief Executive Officer Robert G. Finizio will provide an overview of the company at the conferences.
Feb 21, 2019 04:05 pm ET
TherapeuticsMD Announces Fourth Quarter and Full-Year 2018 Financial Results
TherapeuticsMD, Inc. (NASDAQ:TXMD), an innovative, leading women’s healthcare company, today announced its commercial and corporate update for the fourth quarter and full-year ended December 31, 2018.
Feb 08, 2019 07:00 am ET
TherapeuticsMD to Report Fourth Quarter and Full Year 2018 Results on February 21, 2019
TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women’s healthcare company, today announced that it will report its fourth quarter and full year 2018 financial results on Thursday, February 21, 2019, after the closing of the U.S. financial markets. Following the announcement, executive management will host a conference call and webcast at 4:30 p.m. ET on such date to discuss the Company’s financial results and provide a business update.
Jan 03, 2019 07:00 am ET
TherapeuticsMD Announces Participation at 37th Annual J.P. Morgan Healthcare Conference
TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women’s healthcare company, today announced that the company will participate in the 37th Annual J.P. Morgan Healthcare Conference. Chief Executive Officer Robert G. Finizio will provide an overview of the company at the conference.
Dec 03, 2018 08:00 am ET
Detailed Research: Economic Perspectives on TESARO, Regeneron Pharmaceuticals, Pool, Zebra Technologies, Cadence Design, and TherapeuticsMD — What Drives Growth in Today's Competitive Landscape
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of TESARO, Inc. (NASDAQ:TSRO), Regeneron Pharmaceuticals, Inc....
Nov 12, 2018 04:30 pm ET
TherapeuticsMD Announces Participation in Three Upcoming Investor Conferences
TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women’s healthcare company, today announced that the company will participate in three upcoming healthcare investor conferences. Chief Executive Officer Robert G. Finizio will provide an overview of the company at the conferences.
Nov 07, 2018 04:05 pm ET
TherapeuticsMD Announces Third Quarter 2018 Financial Results
TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women’s healthcare company, today announced its clinical and corporate update for the quarter ended September 30, 2018.
Oct 30, 2018 07:00 am ET
TherapeuticsMD to Report Third Quarter 2018 Financial Results on November 7, 2018
TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women’s healthcare company, today announced that it will report its third quarter 2018 financial results on Wednesday, November 7, 2018, after the closing of the U.S. financial markets. Following the announcement, executive management will host a conference call and webcast at 4:30 p.m. ET on such date to discuss the Company’s financial results and provide a business update.
Oct 29, 2018 09:31 am ET
Thinking about buying stock in Apple, International Business Machines, Square Incorporated, TherapeuticsMD Inc or Yulong Eco-Materials?
NEW YORK, Oct. 29, 2018 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AAPL, IBM, SQ, TXMD, and YECO.
Oct 29, 2018 06:00 am ET
TherapeuticsMD Announces FDA Approval of TX-001HR: BIJUVA™ (Estradiol and Progesterone) Capsules for the Treatment of Moderate to Severe Vasomotor Symptoms Due to Menopause
TherapeuticsMD, Inc. (NASDAQ:TXMD), an innovative women’s healthcare company, today announced that the United States Food and Drug Administration (FDA) has approved BIJUVA™ (estradiol and progesterone) capsules, 1 mg/100 mg, the first and only FDA-approved bio-identical* hormone therapy combination of estradiol and progesterone in a single, oral capsule for the treatment of moderate to severe vasomotor symptoms (commonly known as hot flashes or flushes) due to menopause in women with a uterus.
Oct 24, 2018 08:25 am ET
Consolidated Research: 2018 Summary Expectations for Novavax, Caesars Entertainment, SeaWorld Entertainment, LendingTree, CVS Health, and TherapeuticsMD — Fundamental Analysis, Key Performance Indicat
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Novavax, Inc. (NASDAQ:NVAX), Caesars Entertainment Corporation...
Sep 28, 2018 07:00 am ET
TherapeuticsMD Announces Multiple Presentations Related to Imvexxy™ and TX-001HR at the 2018 Annual Meeting of the North American Menopause Society
TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women’s healthcare company, today announced the schedule of ten oral presentations and posters at NAMS 2018, the annual meeting of the North American Menopause Society being held in San Diego, California on October 3-6, 2018, related to ImvexxyTM (estradiol vaginal inserts) and TX-001HR, the Company’s investigational bio-identical hormone therapy combination of estradiol and progesterone in a single, oral softgel for the treatment of moderate-to-severe vasomotor symptoms due to menopa
Sep 27, 2018 04:05 pm ET
TherapeuticsMD Enters Into Label Discussions for TX-001HR
TherapeuticsMD, Inc. (NASDAQ:TXMD), an innovative women’s healthcare company, today announced that the Company has entered into discussions with the U.S. Food and Drug Administration (FDA) regarding the proposed label for TX-001HR, the Company’s investigational bio-identical hormone therapy combination of estradiol and progesterone in a single, oral softgel for the treatment of moderate-to-severe vasomotor symptoms due to menopause. As previously announced, the Prescription Drug User Fee Act (PDUFA) target action date for the completion of the F
Sep 25, 2018 07:00 am ET
TherapeuticsMD to Present at 2018 Cantor Global Healthcare Conference
TherapeuticsMD, Inc. (NASDAQ:TXMD), an innovative women’s healthcare company, today announced that the company will participate in the 2018 Cantor Global Healthcare Conference being held on October 1-3, 2018. Chief Executive Officer Robert G. Finizio will participate in the conference.
Sep 20, 2018 07:00 am ET
TherapeuticsMD Announces the FDA has Granted AnnoveraTM Marketing Exclusivity as a New Chemical Entity
TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women’s healthcare company, today announced that AnnoveraTM (segesterone acetate and ethinyl estradiol vaginal system) has been granted marketing exclusivity as a new chemical entity (NCE) from the U.S. Food and Drug Administration. The five-year NCE exclusivity runs for five years from the FDA approval of the New Drug Application for Annovera.
Sep 13, 2018 07:00 am ET
TherapeuticsMD Announces Commercial Availability of Imvexxy™ 4 mcg
TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women’s healthcare company, today announced the commercial availability of Imvexxy™ (estradiol vaginal inserts) 4 mcg dose in the United States. Imvexxy 4 mcg is the lowest dose vaginal estrogen product approved by the U.S. Food and Drug Administration (FDA) for treatment of moderate-to-severe dyspareunia (vaginal pain associated with sexual activity), a symptom of vulvar and vaginal atrophy (VVA), due to menopause. Imvexxy is the only product in its therapeutic class to offer a 4 mcg and 10 mcg
Aug 22, 2018 07:00 am ET
TherapeuticsMD to Present at 13th Annual Wells Fargo Securities Healthcare Conference
TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women’s healthcare company, today announced that the company will present at the 13th Annual Wells Fargo Securities Healthcare Conference being held on September 5-6, 2018 in Boston. Robert G. Finizio, Chief Executive Officer, and Brian Bernick, M.D., Co-founder, will participate in the conference.
Aug 10, 2018 03:05 pm ET
TherapeuticsMD Announces FDA Approval of ANNOVERA™ (Segesterone Acetate/Ethinyl Estradiol Vaginal System) for Birth Control
TherapeuticsMD, Inc. (NASDAQ:TXMD), an innovative women’s healthcare company, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved ANNOVERA™ (segesterone acetate/ethinyl estradiol vaginal system), the first long-acting prescription birth control that is patient-controlled, procedure-free and reversible. The ANNOVERA contraceptive vaginal system is a small, soft flexible ring that prevents ovulation for an entire year (13 cycles) and can be inserted and removed by a woman at her discretion in repeated four
Aug 06, 2018 04:05 pm ET
TherapeuticsMD Announces Closing of its Underwritten Public Offering and Concurrent Registered Direct Offering of Common Stock
TherapeuticsMD, Inc. (NASDAQ:TXMD) today announced the closing of its previously announced $65 million underwritten public offering of common stock, at a price to the public of $5.10 per share, and concurrent $20 million registered direct offering of common stock to a strategic investor at a price of $5.10 per share. In connection with the underwritten public offering, TherapeuticsMD granted the underwriters an option to purchase up to an additional 1,911,764 shares of common stock at the public offering price less the underwriting discount, whi
Aug 01, 2018 09:36 pm ET
TherapeuticsMD Announces Pricing of Its Underwritten Public Offering and Concurrent Registered Direct Offering for Aggregate Gross Proceeds of $85 Million
TherapeuticsMD, Inc. (NASDAQ: TXMD) today announced the pricing of its previously announced $65 million underwritten public offering of common stock at a price to the public of $5.10 per share. The price per share to be paid by the strategic investor in the previously announced concurrent $20 million registered direct offering is also $5.10 per share. In addition, TherapeuticsMD has granted to the underwriters of the underwritten public offering an option for a period of 30 days to purchase, at the public offering price less the underwriting dis
Jul 31, 2018 04:15 pm ET
TherapeuticsMD Licenses Population Council’s Novel Segesterone Acetate/ Ethinyl Estradiol One-Year Vaginal Contraceptive System
TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women’s healthcare company, today announced that it has entered into an exclusive license agreement with the Population Council to commercialize its investigational segesterone acetate/ ethinyl estradiol one-year vaginal system for contraception in the United States (U.S.). The one-year vaginal contraceptive system is in the shape of a ring and combines a novel progestin, segesterone acetate (Nestorone®), with a widely used estrogen to prevent ovulation for an entire year (13 cycles).
Jul 31, 2018 04:13 pm ET
Knight Therapeutics and TherapeuticsMD Announce Strategic Partnership
Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a Canadian specialty pharmaceutical company, and TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women’s healthcare company, today announced that they have entered into a licensing agreement that grants Knight the rights to commercialize TX-004HR and TX-001HR in Canada and Israel.
Jul 31, 2018 04:12 pm ET
Knight Therapeutics and TherapeuticsMD Announce Strategic Partnership
Knight Therapeutics Inc. (TSX:GUD) (“Knight”), a Canadian specialty pharmaceutical company, and TherapeuticsMD, Inc. (NASDAQ:TXMD), an innovative women’s healthcare company, today announced that they have entered into a licensing agreement that...
Jul 31, 2018 04:09 pm ET
TherapeuticsMD Announces Proposed $65 Million Underwritten Public Offering and Concurrent $20 Million Registered Direct Offering of Common Stock
TherapeuticsMD, Inc. (NASDAQ:TXMD) today announced the launch of a $65 million underwritten public offering and a concurrent $20 million registered direct offering to a strategic investor of shares of its common stock. TherapeuticsMD also expects to grant the underwriters of the underwritten public offering a 30-day option to purchase up to an additional 15% of shares of common stock offered in the underwritten public offering. All of the shares in the offerings are to be sold by TherapeuticsMD. Both offerings are subject to market conditions, a
Jul 30, 2018 06:15 am ET
TherapeuticsMD Announces Second Quarter 2018 Financial Results
TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women’s healthcare company, today announced its financial results for the quarter ended June 30, 2018.
Jul 25, 2018 07:00 am ET
TherapeuticsMD to Report Second Quarter 2018 Financial Results on July 30, 2018
TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women’s healthcare company, today announced that it will report its second quarter 2018 financial results on Monday, July 30, 2018, before the opening of the U.S. financial markets. Following the announcement, executive management will host a conference call and webcast at 8:30 a.m. ET on such date to discuss the Company’s financial results and provide a business update.
Jun 07, 2018 04:05 pm ET
TherapeuticsMD Announces Draw Down of $75 Million Under Term Loan with MidCap Financial
TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women’s healthcare company, today announced that the company has completed the first draw down of $75 million under its previously announced $200 million term loan facility with MidCap Financial, managed by Apollo Capital Management, L.P. The Company intends to use the proceeds from the financing to support the commercial launch of its recently approved product, Imvexxy™ (estradiol vaginal inserts) for the treatment of moderate-to-severe dyspareunia (vaginal pain associated with sexual ac
Jun 07, 2018 07:00 am ET
TherapeuticsMD to Present at Goldman Sachs 39th Annual Global Healthcare Conference
TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women’s healthcare company, today announced that the company will present at the Goldman Sachs 2018 Global Healthcare Conference being held on June 12-14, 2018 in Rancho Palos Verdes, CA. Chief Executive Officer Robert G. Finizio will participate in the conference.
Jun 06, 2018 07:00 am ET
TherapeuticsMD Announces Multiple Presentations at the International Menopause Society’s 16th World Congress
TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women’s healthcare company, today announced the schedule of seven presentations at the International Menopause Society’s 16th World Congress on Menopause related to clinical data for Imvexxy™ (estradiol vaginal inserts) (formerly TX-004HR), an applicator-free, ultra-low dose estradiol softgel vaginal insert, and TX-001HR, the Company’s investigational bio-identical oral combination of estradiol and progesterone for the treatment of moderate-to-severe vasomotor symptoms (VMS) du
Jun 04, 2018 04:30 pm ET
TherapeuticsMD to Present at Jefferies 2018 Healthcare Conference
TherapeuticsMD, Inc. (NASDAQ:TXMD), an innovative women’s healthcare company, today announced that the company will present at the Jefferies 2018 Healthcare Conference being held on June 5-8, 2018. Chief Executive Officer Robert G. Finizio and Chief Clinical Officer Brian Bernick, M.D. will participate at the conference.
May 31, 2018 04:10 pm ET
TherapeuticsMD Announces Clinical Abstract at the 2018 ASCO Annual Meeting
TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women’s healthcare company, today announced the availability of clinical data from the REJOICE trial for IMVEXXY™ (estradiol vaginal inserts) (formerly TX-004HR). TherapeuticsMD will highlight a substudy of the REJOICE trial that evaluated the pharmacokinetics of IMVEXXY 4 mcg, 10 mcg, and placebo. IMVEXXY was recently approved by the United States Food and Drug Administration (FDA) for the treatment of moderate-to-severe vaginal pain associated with sexual activity (dyspareunia), a symptom of
May 30, 2018 09:37 am ET
TherapeuticsMD Announces FDA Approval of TX-004HR: IMVEXXY™ (estradiol vaginal inserts), the Lowest Dose Vaginal Estrogen Product Approved for the Treatment of Moderate to Severe Dyspareunia, a Sympto
BOCA RATON, Fla., May 30, 2018 /PRNewswire/ -- TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women's healthcare company, today announced that the United States Food and Drug Administration (FDA) has approved IMVEXXY™ (estradiol vaginal inserts) for the treatment of moderate-to-severe dyspareunia (vaginal pain associated with sexual activity), a symptom of vulvar and vaginal atrophy (VVA), due to menopause. IMVEXXY is the only product in its therapeutic class to offer a 4 mcg and 10 mcg dose, the 4 mcg representing the lowest approved dose of vaginal estradiol available.
May 30, 2018 06:00 am ET
TherapeuticsMD Announces FDA Approval of TX-004HR: IMVEXXY (estradiol vaginal inserts), the Lowest Dose Vaginal Estrogen Product Approved for the Treatment of Moderate to Severe Dyspareunia, a Symptom
TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women’s healthcare company, today announced that the United States Food and Drug Administration (FDA) has approved IMVEXXY (estradiol vaginal inserts) for the treatment of moderate-to-severe dyspareunia (vaginal pain associated with sexual activity), a symptom of vulvar and vaginal atrophy (VVA), due to menopause. IMVEXXY is the only product in its therapeutic class to offer a 4 mcg and 10 mcg dose, the 4 mcg representing the lowest approved dose of vaginal estradiol available.
May 23, 2018 12:38 pm ET
TherapeuticsMD Comments on Media Reports Regarding TX-004HR
TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women’s healthcare company, today commented on media reports that TX-004HR, the company’s investigational applicator-free estradiol vaginal softgel capsule for the treatment of moderate-to-severe vaginal pain during sexual activity (dyspareunia), a symptom of vulvar and vaginal atrophy (VVA) due to menopause, has been approved by the U.S. Food and Drug Administration (FDA).
May 16, 2018 04:30 pm ET
TherapeuticsMD Announces Investor and Analyst Day on June 4
TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women’s healthcare company, today announced that the Company will host an Investor and Analyst Day on Monday, June 4, 2018, in New York City.
May 03, 2018 04:05 pm ET
TherapeuticsMD Announces First Quarter 2018 Financial Results
TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women’s healthcare company, today announced its financial results for the quarter ended March 31, 2018.
May 01, 2018 04:30 pm ET
TherapeuticsMD to Host First Quarter Financial Results Conference Call and Webcast on May 3
TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women’s healthcare company, today announced that it will host a conference call and live audio webcast to discuss its first quarter financial and business results on Thursday, May 3. The conference call and webcast will take place at 4:30 p.m. Eastern Time (ET). TherapeuticsMD Chief Executive Officer Robert G. Finizio and Chief Financial Officer Dan Cartwright will host the call.
Apr 11, 2018 06:00 am ET
TherapeuticsMD Enters Into Label Negotiations for TX-004HR
TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women’s healthcare company, today announced that the Company has entered into negotiations with the U.S. Food and Drug Administration (FDA) regarding the proposed label for TX-004HR, the Company’s investigational applicator-free estradiol vaginal softgel capsule for the treatment of moderate-to-severe vaginal pain during sexual intercourse (dyspareunia), a symptom of vulvar and vaginal atrophy (VVA) due to menopause. As previously announced, the Prescription Drug User Fee Act (PDUFA) target
Apr 02, 2018 07:00 am ET
TherapeuticsMD Announces Expansion of Board of Directors
TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women’s healthcare company, today announced the appointment of Jane F. Barlow, M.D., M.B.A., M.P.H. as an independent director to the Board of Directors.
Mar 08, 2018 04:15 pm ET
TherapeuticsMD Announces FDA Acceptance of New Drug Application (NDA) and Prescription Drug User Fee Act (PDUFA) Date for TX-001HR
TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women’s healthcare company, today announced the acceptance of the NDA for TX-001HR by the U.S. Food and Drug Administration (FDA). TX-001HR is the company’s investigational bio-identical hormone therapy combination of estradiol and progesterone in a single, oral softgel for the treatment of moderate-to-severe vasomotor symptoms due to menopause.
Mar 06, 2018 04:30 pm ET
TherapeuticsMD to Present at Two Upcoming Investor Conferences
TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women’s healthcare company, today announced that the Company will participate in the Cowen and Company 38th Annual Healthcare Conference on March 12, and the Oppenheimer 28th Annual Healthcare Conference on March 20. Chief Executive Officer Robert G. Finizio and Chief Clinical Officer Brian Bernick, M.D., will participate.
Feb 20, 2018 04:05 pm ET
TherapeuticsMD Announces Fourth Quarter and Full Year 2017 Financial Results
TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women’s healthcare company, today announced its fourth quarter and full-year financial results for 2017.
Feb 20, 2018 12:00 pm ET
TherapeuticsMD, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / February 20, 2018 / TherapeuticsMD, Inc. (NASDAQ: TXMD) will be discussing their earnings results in their Q4 Earnings Call to be held on February 20, 2018 at 4:30 PM Eastern Time.
Feb 15, 2018 07:45 am ET
Research Report Identifies Louisiana-Pacific, Vmware, ZAGG, FS Investment, TherapeuticsMD, and Kennedy-Wilson with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
NEW YORK, Feb. 15, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Louisiana-Pacific Corporation (NYSE:LPX), Vmware, Inc. (NYSE:VMW),...
Feb 06, 2018 04:30 pm ET
TherapeuticsMD to Host Fourth Quarter and Year End 2017 Financial Results Conference Call and Webcast on February 20
TherapeuticsMD, Inc. (NASDAQ:TXMD), an innovative women’s healthcare company, today announced that it will host a conference call and live audio webcast to discuss its fourth quarter and year end 2017 financial and business results on Tuesday, February 20. The conference call and webcast will take place at 4:30 p.m. Eastern Time (ET). TherapeuticsMD Chief Executive Officer Robert G. Finizio and Chief Financial Officer Dan Cartwright will host the call.
Jan 03, 2018 04:30 pm ET
TherapeuticsMD Announces Presentation at 36th Annual J.P. Morgan Healthcare Conference on January 10
TherapeuticsMD, Inc. (NASDAQ:TXMD), an innovative women’s healthcare company, today announced that the company will present at the 36th Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2018 in San Francisco. Chief Executive Officer Robert G. Finizio and Chief Clinical Officer Brian Bernick, M.D. will participate.
Dec 28, 2017 04:30 pm ET
TherapeuticsMD Announces Submission of New Drug Application for TX-001HR
TherapeuticsMD, Inc. (NASDAQ:TXMD), an innovative women’s healthcare company, announced today that it has submitted the New Drug Application (NDA) for TX-001HR, the company’s investigational bio-identical hormone therapy combination of estradiol and progesterone in a single, oral softgel for the treatment of moderate-to-severe vasomotor symptoms due to menopause, with the U.S. Food and Drug Administration (FDA).
Dec 19, 2017 04:36 pm ET
TherapeuticsMD Announces FDA Acceptance of New Drug Application and Prescription Drug User Fee Act (PDUFA) Date for TX-004HR
TherapeuticsMD, Inc. (NASDAQ:TXMD), an innovative women’s healthcare company, today announced the acceptance of the New Drug Application (NDA) resubmission for TX-004HR, the company’s investigational applicator-free estradiol vaginal softgel capsule for the treatment of moderate-to-severe vaginal pain during sexual intercourse (dyspareunia), a symptom of vulvar and vaginal atrophy (VVA) due to menopause, by the U.S. Food and Drug Administration (FDA).
Dec 01, 2017 07:30 am ET
Recent Analysis Shows FS Investment, TherapeuticsMD, Kennedy-Wilson, Louisiana-Pacific, Vmware, and ZAGG Market Influences — Renewed Outlook, Key Drivers of Growth
NEW YORK, Dec. 01, 2017 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of FS Investment Corporation (NYSE:FSIC), TherapeuticsMD, Inc....
Nov 29, 2017 04:30 pm ET
TherapeuticsMD Announces Resubmission of New Drug Application for TX-004HR
TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women’s healthcare company, announced today that it has resubmitted the New Drug Application (NDA) for TX-004HR, the company’s investigational applicator-free estradiol vaginal softgel capsule for the treatment of moderate-to-severe vaginal pain during sexual intercourse (dyspareunia), a symptom of vulvar and vaginal atrophy (VVA) due to menopause, with the U.S. Food and Drug Administration (FDA).
Nov 07, 2017 04:30 pm ET
TherapeuticsMD to Present at Two Upcoming Investor Conferences
TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women’s healthcare company, today announced that the company will participate in the Stifel 2017 Healthcare Conference on November 14, and the Jefferies 2017 London Healthcare Conference on November 15-16. Chief Executive Officer Robert G. Finizio and Chief Clinical Officer Brian Bernick, M.D., will participate in both conferences.
Nov 06, 2017 06:05 am ET
TherapeuticsMD Announces Third Quarter 2017 Financial Results
TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women’s healthcare company, today announced its financial results for the quarter ended September 30, 2017.
Nov 06, 2017 06:00 am ET
TherapeuticsMD Announces Plan to Resubmit the New Drug Application for TX-004HR
TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women’s healthcare company, today announced a regulatory update regarding the New Drug Application (NDA) for TX-004HR, the Company’s investigational applicator-free estradiol vaginal softgel capsule for the treatment of moderate-to-severe vaginal pain during sexual intercourse (dyspareunia), a symptom of vulvar and vaginal atrophy (VVA) due to menopause.
Nov 03, 2017 04:05 pm ET
TherapeuticsMD to Host TX-004HR Regulatory Update and Third Quarter Financial Results Conference Call and Webcast on November 6
TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women’s healthcare company, today announced that it will host a conference call and live audio webcast to discuss a TX-004HR regulatory update and third quarter financial and business results on Monday, November 6. The conference call and webcast will take place at 8:00 a.m. Eastern Time (ET). TherapeuticsMD Chief Executive Officer Robert G. Finizio and Chief Financial Officer Dan Cartwright will host the call.
Oct 05, 2017 06:45 am ET
TherapeuticsMD Announces Multiple Presentations Related to TX-004HR and TX-001HR at NAMS 2017
TherapeuticsMD, Inc. (NYSE American:TXMD), an innovative women’s healthcare company, today announced the schedule of nine presentations at NAMS 2017, the annual meeting of the North American Menopause Society, in Philadelphia, Pennsylvania, October 11-14, related to TX-004HR, the company’s investigational applicator-free vaginal estradiol softgel capsule in development for the treatment of moderate-to-severe vaginal pain during sexual intercourse (dyspareunia), a symptom of vulvar and vaginal atrophy (VVA), due to menopause, and TX-001HR,
Jun 08, 2017 05:14 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against TherapeuticsMD, Inc. and Certain Officers – TXMD
NEW YORK, June 08, 2017 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NYSE:TXMD) and certain of its officers.   The class action, filed in United States District Court, Southern District of Florida, and docketed under 17-cv-80720, is on behalf of a class consisting of investors who purchased or otherwise acquired TherapeuticsMD securities, seeking to recover compensable damages caused by defendants’ violations of the Securities Exchange Act of 1934....
May 24, 2017 02:49 pm ET
IMPORTANT THERAPEUTICSMD, INC. INVESTOR REMINDER: Wolf Haldenstein Adler Freeman & Herz LLP reminds investors that a securities class action lawsuit has been filed in the United States District Court
NEW YORK, May 24, 2017 (GLOBE NEWSWIRE) -- Wolf Haldenstein Adler Freeman & Herz LLP announces that a class action complaint was filed against TherapeuticsMD, Inc. (NYSE MKT:TXMD) in the United States District Court for the Southern District of Florida, on behalf of all purchasers of TherapeuticsMD securities between July 7, 2016 and April 9, 2017, inclusive (“Class Period”)....
May 15, 2017 09:00 am ET
The Klein Law Firm Announces a Class Action Filed on Behalf of TherapeuticsMD, Inc. Shareholders and a Lead Plaintiff Deadline of June 19, 2017
NEW YORK, May 15, 2017 (GLOBE NEWSWIRE) -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of TherapeuticsMD, Inc. (NYSEMKT:TXMD) who purchased shares between July 7, 2016 and April 9, 2017. The action, which was filed in the USDC for the Southern District of Florida, alleges that the Company violated federal securities laws....
May 10, 2017 12:08 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of TherapeuticsMD, Inc. - TXMD
NEW YORK, May 10, 2017 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of TherapeuticsMD, Inc. ("TherapeuticsMD" or the "Company") (NYSE:  TXMD).   Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 9980.
May 09, 2017 05:38 pm ET
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Investing In TherapeuticsMD, Inc. To Contact The Firm
NEW YORK, May 9, 2017 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in TherapeuticsMD, Inc. ("TherapeuticsMD" or the "Company") (NYSE-MKT: TXMD) of the June 19, 2017 deadline to seek the role of lead plaintiff in a federal securities class action lawsuit filed against the Company and certain officers.
May 03, 2017 03:43 pm ET
IMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces a Securities Class Action Lawsuit against TherapeuticsMD, Inc. and Encourages Investors with Losses to Contact the Firm
IRVINE, Calif., May 3, 2017 /PRNewswire/ -- Khang & Khang LLP (the "Firm") announces the filing of a class action lawsuit against TherapeuticsMD, Inc. ("TherapeuticsMD" or the "Company") (NYSE: TXMD). Investors who purchased or otherwise acquired shares between July 7, 2016 and April 9, 2017, inclusive (the "Class Period"), are encouraged to contact the Firm in advance of the June 19, 2017 lead plaintiff motion deadline.
May 02, 2017 05:41 pm ET
IMPORTANT EQUITY ALERT: Lundin Law PC Announces a Securities Class Action Lawsuit against TherapeuticsMD, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, May 2, 2017 /PRNewswire/ -- Lundin Law PC , a shareholder rights firm, announces the filing of a class action lawsuit against TherapeuticsMD, Inc. ("TherapeuticsMD" or the "Company") (NYSE: TXMD) concerning possible violations of federal securities laws between July 7, 2016 and April 9, 2017 inclusive (the "Class Period"). Investors who purchased or otherwise acquired the Company's shares during the Class Period should contact the firm prior to the June 19, 2017 lead plaintiff motion deadline.
Apr 29, 2017 12:00 am ET
IMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces a Securities Class Action Lawsuit against TherapeuticsMD, Inc. and Encourages Investors with Losses to Contact the Firm
IRVINE, Calif., April 29, 2017 (GLOBE NEWSWIRE) -- Khang & Khang LLP (the “Firm”) announces the filing of a class action lawsuit against TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NYSE:TXMD). Investors who purchased or otherwise acquired shares between July 7, 2016 and April 9, 2017, inclusive (the “Class Period”), are encouraged to contact the Firm in advance of the June 19, 2017 lead plaintiff motion deadline....
Apr 26, 2017 07:00 pm ET
RM LAW Announces Class Action Lawsuit Against TherapeuticsMD, Inc.
BERWYN, Pa., April 26, 2017 /PRNewswire/ -- RM LAW, P.C. announces that a class action lawsuit has been filed in United States District Court for the Southern District of Florida on behalf of all persons or entities that purchased TherapeuticsMD, Inc. ("TherapeuticsMD" or the "Company") (NYSE MKT: TXMD) securities between July 7, 2016 and April 9, 2017, inclusive (the "Class Period").
Apr 25, 2017 03:05 pm ET
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against TherapeuticsMD, Inc. (TXMD) & Lead Plaintiff Deadline: June 19, 2017
NEW YORK, April 25, 2017 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against TherapeuticsMD, Inc. ("TherapeuticsMD" or the "Company") (NYSE: TXMD) securities and certain of its officers, on behalf of a class who purchased TherapeuticsMD securities between July 7, 2016 and April 9, 2017, (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site: www.bgandg.com/txmd.
Apr 24, 2017 03:16 pm ET
The Klein Law Firm Announces a Class Action Filed on Behalf of TherapeuticsMD, Inc. Shareholders and a Lead Plaintiff Deadline of June 19, 2017
NEW YORK, April 24, 2017 (GLOBE NEWSWIRE) -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of TherapeuticsMD, Inc. (NYSEMKT:TXMD) who purchased shares between July 7, 2016 and April 9, 2017. The action, which was filed in the USDC for the Southern District of Florida, alleges that the Company violated federal securities laws....
Apr 20, 2017 06:00 pm ET
IMPORTANT THERAPEUTICSMD, INC. INVESTOR ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed in the United States District Court for the Sou
NEW YORK, April 20, 2017 (GLOBE NEWSWIRE) -- Wolf Haldenstein Adler Freeman & Herz LLP announces that a class action complaint was filed against TherapeuticsMD, Inc. (NYSE MKT:TXMD) in the United States District Court for the Southern District of Florida, on behalf of all purchasers of TherapeuticsMD securities between July 7, 2016 and April 9, 2017, inclusive (“Class Period”)....
Apr 20, 2017 02:00 pm ET
TXMD SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notifies Investors of Commencement of a Class Action Involving TherapeuticsMD, Inc. and a Lead Plaintiff Deadline of June 19, 2017
NEW YORK, April 20, 2017 (GLOBE NEWSWIRE) -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Southern District of Florida on behalf of investors who purchased TherapeuticsMD, Inc. ("TherapeuticsMD") (NYSEMKT:TXMD) securities between July 7, 2016 and April 9, 2017....

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.